Capital Fund Management (CFM)
OCUL icon

Capital Fund Management (CFM)’s Ocular Therapeutix OCUL Stock Holding History

Capital Fund Management (CFM)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,000
Closed -$167K – 1935
2017
Q3 		$167K Buy
+27,000
New +$174K ﹤0.01% 1467

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Fund Management (CFM)'s OCUL Position: Q4 2017 in Review

Capital Fund Management (CFM) sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 27,000 shares — an estimated $167K sold.

Capital Fund Management (CFM) first reported a position in OCUL in Q3 2017 and held it in 1 quarter. The position peaked at $167K in Q3 2017. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

  • Capital Fund Management (CFM) reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 27,000 Ocular Therapeutix shares in Q4 2017, an estimated $167K.
  • Capital Fund Management (CFM) first reported a position in Ocular Therapeutix in Q3 2017 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Ocular Therapeutix position peaked at $167K in Q3 2017.
  • 69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2017, filed 9 Feb 2018.